[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, Takano Y: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch; 2008 May;452(5):525-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas.
  • To investigate the pathobiological behaviors of gastric mixed-type (MT) carcinomas and gastric carcinogenesis, the clinicopathological characteristics of MT carcinomas were analyzed and compared with intestinal-type (IT) and diffuse-type (DT) carcinomas.
  • The expression of Ki-67, caspase-3, p53, fragile histine triad (FHIT), maspin, extracellular matrix metalloproteinase inducer (EMMPRIN), vascular growth factor (VEGF), MUC-2, 4, 5AC and 6, CD44, E-cadherin, beta-catenin, and phosphorylated glycogen synthase kinase 3beta-ser9 (P-GSK3beta-ser9) was examined on tissue microarrays using immunohistochemistry.
  • It was found that MT carcinomas exhibited large size, deep invasion, frequent local invasion, and lymph node metastasis in comparison with IT and DT carcinomas (p < 0.05).
  • All the markers except MUC-5AC showed higher expression in IT than DT carcinomas (p < 0.05).
  • The MT diffuse component displayed a higher expression of FHIT, VEGF, and P-GSK3beta-ser9 than DT carcinoma (p < 0.05).
  • The accumulative survival rate of the IT carcinoma patients was higher than the other types (p < 0.05).
  • The invasive depth, venous invasion, lymph node, peritoneal or liver metastasis, and Lauren's classification were independent prognostic factors for gastric carcinomas (p < 0.05).
  • These findings suggested that MT carcinomas were also indicated to be more aggressive than IT and DT carcinomas.
  • Significant differences were observed in the proliferation, apoptosis, angiogenesis, mucin secretion, and cell adhesion between IT and DT carcinomas, whereas only a few of these characteristics showed differences between the MT intestinal and diffuse parts, thus suggesting that both the MT components might originate from the stem cells with similar genetic traits, but follow different histogenic pathways.
  • [MeSH-major] Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Malignant / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Biomarkers, Tumor / metabolism. Cell Adhesion. Cell Proliferation. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Protein Array Analysis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1995 Jul;191(6):571-84 [7479380.001]
  • [Cites] Oncology. 1995 Jul-Aug;52(4):334-9 [7539903.001]
  • [Cites] Gen Diagn Pathol. 1997 Jul;143(1):39-48 [9269907.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):114-33; discussion 133 [15895459.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):363-71 [16489634.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3B):2353-60 [16821616.001]
  • [Cites] Gastric Cancer. 2006;9(3):177-84 [16952035.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1A):259-65 [17352241.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] J Pathol. 2000 Mar;190(4):437-43 [10699992.001]
  • [Cites] Br J Surg. 2000 May;87(5):618-26 [10792320.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):75-8 [11205493.001]
  • [Cites] Chem Rev. 2001 Aug;101(8):2527-40 [11749387.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1415-20 [12854132.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] IARC Sci Publ. 2004;(157):327-49 [15055305.001]
  • [Cites] J Pathol. 2004 Jun;203(2):681-7 [15141383.001]
  • [Cites] Gastric Cancer. 2004;7(2):61-77 [15224192.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1989 Jan;11(1):37-40 [2550197.001]
  • [Cites] Cancer. 1990 May 1;65(9):2086-90 [2372774.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;120(1-2):103-11 [7903667.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • (PMID = 18266006.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2329735
  •  go-up   go-down


2. Park S, Shin SJ, Ahn JB, Jeung HC, Rha SY, Lee SK, Chung HC: Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction. Yonsei Med J; 2009 Apr 30;50(2):296-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction.
  • Malignant obstruction develops frequently in advanced gastric cancer.
  • Although it is primarily the gastric outlet that is obstructed, there are occasional reports of colonic obstruction.
  • Nevertheless, endoscopic stent insertion could be a better treatment than emergency surgery in cases of malignant bowel obstruction in cancer patients with poor performance status.
  • We report a case of advanced gastric cancer with carcinomatosis in which a recurrent colonic stent was inserted at the same site because of cancer growth into the stent.
  • The patient maintained a good condition for chemotherapy, thus improving their chances for survival.
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Recurrence, Local. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2000 Jun;30(4):364-71 [10875463.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):24-30 [17592286.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Endoscopy. 2003 Jan;35(1):79-85 [12510232.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):67-71 [15201961.001]
  • [Cites] Br Med J. 1977 Jan 29;1(6056):266-7 [65197.001]
  • [Cites] J Clin Gastroenterol. 2005 Feb;39(2):124-8 [15681907.001]
  • [Cites] J Clin Gastroenterol. 2005 Nov-Dec;39(10):877-85 [16208111.001]
  • [Cites] J Gastroenterol. 2005 Oct;40(10):932-7 [16261429.001]
  • [Cites] Surg Endosc. 2006 Jun;20(6):909-14 [16738981.001]
  • [Cites] Br J Surg. 2006 Aug;93(8):907-8 [16845691.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):91-4 [16806783.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):921-4 [17140899.001]
  • [Cites] Endoscopy. 2007 May;39(5):448-54 [17516352.001]
  • [Cites] Radiology. 2001 Jun;219(3):679-83 [11376254.001]
  • (PMID = 19430568.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2678709
  • [Keywords] NOTNLM ; Gastric cancer / benefit / carcinomatosis / colonic stent
  •  go-up   go-down


3. Ruiz-Hernández G, Delgado-Bolton RC, Rubio-Pérez MJ, Jiménez-Vicioso A, Pérez-Castejón MJ, Carreras-Delgado JL: [Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET]. Rev Esp Med Nucl; 2005 Sep-Oct;24(5):326-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent signet-ring cell gastric carcinoma evidenced by FDG-PET].
  • OBJECTIVE: To present the case report of a patient with undifferentiated and diffuse signet-ring cell gastric carcinoma in which FDG-PET evidenced recurrent disease.
  • MATERIALS AND METHODS: The patient was diagnosed of a stage III gastric carcinoma in 1994 and was treated with a subtotal gastrectomy.
  • The patient was treated with chemotherapy and radiotherapy, reaching a complete response.
  • RESULTS: FDG-PET detected pathologic findings suggestive of malignant disease in right supraclavicular and mediastinal lymph nodes.
  • CONCLUSIONS: In this case report we stress the importance of early recurrence by FDG-PET in a non-intestinal gastric carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194466.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Hauenstein E, Seidl S, Schneider KT, Fischer T: Stillbirth in week 19 of pregnancy followed by maternal death as a consequence of refused chemotherapy for non-hodgkin's lymphoma--significance of adjuvant chemotherapy in women of reproductive age. Onkologie; 2010;33(12):692-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stillbirth in week 19 of pregnancy followed by maternal death as a consequence of refused chemotherapy for non-hodgkin's lymphoma--significance of adjuvant chemotherapy in women of reproductive age.
  • Especially in lymphomas, incidence and long-time survival have increased.
  • Hematologists and gynecologists have to treat more and more female patients who wish to become pregnant despite their disease and/or after finishing treatment.
  • CASE REPORT: We report on a 28-year-old patient with highly malignant non-Hodgkin's lymphoma (peripheral T cell lymphoma, Ann Arbor stage IV) and main manifestation at the gastric antrum, with a distinct wish for becoming pregnant.
  • Chemotherapy was strongly recommended to her, but she refused.
  • After she had conceived, the disease recurred, followed by stillbirth in week 19 of gestation and death due to gastric perforation and septic shock.
  • CONCLUSIONS: Facing the risk of sterility after chemotherapy should not induce patients to refuse chemotherapy and risk their lives.
  • Treatment of young female cancer patients should therefore always include a thorough discussion about other ways of preserving fertility for the time after treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Infertility, Female / chemically induced. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / surgery. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / surgery. Stillbirth. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Treatment Refusal
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Fatal Outcome. Female. Gastrectomy. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / toxicity. Pregnancy. Pregnancy Trimester, Second. Pyloric Antrum / pathology. Rupture, Spontaneous. Shock, Septic / pathology. Stomach Rupture / parasitology. Vincristine / administration & dosage. Vincristine / toxicity


5. Toh U, Fujii T, Mishima M, Imaizumi T, Koga A, Yano S, Shirouzu K, Yahara T, Yamana H: [Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer]. Gan To Kagaku Ryoho; 2007 Nov;34(12):1931-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer].
  • In order to take advantage by both the anticancer effects and reconstruction of antitumor immunity, we compared the feasibility of a combination of CTL transfer and chemotherapy (ChT) for patients (pts) with malignant ascites due to carcinomatous peritonealitis of refractory gastric cancer to that of ChT only and/or cellular immunotherapy after failing ChT.
  • A total of 22 pts, 8 underwent only conventional ChT (Group A), 6 performed cellular IT after failing ChT (Group B) and 8 underwent combination therapy (Group C), were enrolled in this retrospective study.
  • ChT was based on conventional conditioning regimen with a standard dose for gastric cancer cases: S-1 (80-120 mg/body) plus paclitaxel (60-80 mg/m2), or CPT-11 (70-80 mg/m2) plus CDDP (80 mg/m2).
  • Autologous tumor cells stimulated with T lymphocytes (AuTL), a kind of CTL, were generated ex vivo from peripheral blood lymphocytes over a two-week co-culturing process with autologous tumor cells separating from the ascites.
  • The treatment was repeated at least three cycles with one-week interval.
  • Lymphocytes of ascites were evaluated for cytokine production and subset of CD4+CD25+ T cell before the treatment, and after 3 treatments.
  • The group C pts had increased IFN-gamma and IL-12 production with no TGF-beta1 responses by their ascites after 3 treatments.
  • These data show that combination therapy of CTL transfer and ChT is a feasible option for patients with refractory peritoneal carcinomatous of gastric cancer without serious adverse events.
  • Although it depends on each mechanism of IT and ChT, a more stringent evaluation of CTL transfer combined with ChT for refractory gastric cancer should be performed.
  • [MeSH-major] Combined Modality Therapy. Immunotherapy. Stomach Neoplasms / immunology. Stomach Neoplasms / therapy. T-Lymphocytes, Regulatory / immunology. T-Lymphocytes, Regulatory / transplantation
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cells, Cultured. Cytokines / metabolism. Female. Humans. Male. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / immunology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy. RNA, Messenger / genetics. Receptors, Antigen, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219856.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


6. Tong Q, Liu K, Lu XM, Shu XG, Wang GB: Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer. J Biomed Biotechnol; 2010;2010:121094
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer.
  • Antibody-targeted superantigen has been developed into a new strategy to treat many malignant tumors.
  • In this study, for specific targeting to gastric cancer cell, superantigen SEB (Staphylococcal Enterotoxin B) was genetically fused to the single-chain variable fragment of gastric carcinoma-associated antibody MG7(MG7-scFv) that recognizes the MG7 antigen frequently expressed in gastric cancer cell.
  • The recombinant MG7-scFv/SEB fusion proteins are expressed in E. coli as inclusion bodies, and the purified MG7-scFv/SEB retains high binding affinity with gastric cancer cell SGC-7901 (positive MG7 antigen expression).
  • It was observed that gastric-tumor-bearing rats administrated with MG7-scFv/SEB showed more inflammatory cell infiltration, more significant tumor inhibition, and longer survival time than those of rats treated with SEB or NS (Normal Saline).
  • The data indicated that MG7-scFv/SEB fusion protein could specifically target gastric cancer cell, enhance the activity of T cells and induce tumor cell apoptosis to exert the antitumor effect on gastric cancer.
  • [MeSH-major] Antibodies, Neoplasm / metabolism. Antigens, Neoplasm / pharmacology. Enterotoxins / pharmacology. Recombinant Fusion Proteins / pharmacology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Analysis of Variance. Animals. Cell Growth Processes / drug effects. Cloning, Molecular. Cytokines / metabolism. Escherichia coli / genetics. Female. Humans. Necrosis. Neoplasm Transplantation. Neutrophil Infiltration / drug effects. Rats. Rats, Sprague-Dawley. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1993 Sep 1;53(17):4026-34 [7689421.001]
  • [Cites] Cancer Immunol Immunother. 1993;36(2):89-93 [8425213.001]
  • [Cites] Annu Rev Immunol. 1996;14:49-71 [8717507.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2844-9 [9661900.001]
  • [Cites] Q J Nucl Med. 1999 Jun;43(2):132-9 [10429508.001]
  • [Cites] J Nucl Med. 1999 Sep;40(9):1536-46 [10492377.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 1;329(1):168-76 [15721289.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):591-8 [15704106.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3565-73 [16101181.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7724-33 [16885375.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):510-7 [17164226.001]
  • [Cites] Nucl Med Biol. 2008 Feb;35(2):151-8 [18312824.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):199-202 [18304620.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10131-6 [18645180.001]
  • [Cites] Cancer Invest. 2009 May;27(4):376-83 [19160106.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):280-5 [10640958.001]
  • [Cites] J Immunol Methods. 1999 Dec 10;231(1-2):249-60 [10648942.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6964-71 [11156397.001]
  • [Cites] Exp Biol Med (Maywood). 2001 Mar;226(3):164-76 [11361034.001]
  • [Cites] World J Gastroenterol. 2002 Feb;8(1):99-102 [11833081.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1009-13 [12439915.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] Science. 1988 Oct 21;242(4877):423-6 [3140379.001]
  • [Cites] Cell. 1989 Jan 13;56(1):27-35 [2521300.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Apr 30;168(2):696-701 [2159298.001]
  • [Cites] J Immunol. 1990 Jun 15;144(12):4663-9 [1972165.001]
  • [Cites] Science. 1991 Jun 21;252(5013):1657-62 [2047874.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7228-32 [1871129.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6363-71 [1933899.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3402-8 [1596900.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):801-6 [1436058.001]
  • [Cites] J Exp Med. 1995 Nov 1;182(5):1573-7 [7595227.001]
  • (PMID = 20339532.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Cytokines; 0 / Enterotoxins; 0 / MG7 antigen, human; 0 / Recombinant Fusion Proteins; 39424-53-8 / enterotoxin B, staphylococcal
  • [Other-IDs] NLM/ PMC2843864
  •  go-up   go-down


7. Gérard J, Berdin B, Portier G, Godon A, Tessier-Marteau A, Geneviève F, Zandecki M: [Bone marrow necrosis in two patients with neoplastic disorders]. Ann Biol Clin (Paris); 2007 Nov-Dec;65(6):636-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone marrow necrosis is defined by extensive necrosis of the myeloid tissue and bone marrow stroma.
  • A chemotherapy was started but the patient died 20 days after admission.
  • The second patient, aged 28, has been hospitalized for severe bleeding a few days after the diagnosis of a metastatic gastric tumour.
  • According to literature, bone marrow necrosis is in most instances secondary to either an haematological malignancy (60%) or to a solid tumour (30%), but only at times observed with a non-malignant disorder.
  • Bone pain, fever, cytopenias and elevated serum lactic dehydrogenase and alkaline phosphatase are frequently reported, but are mostly non specific of the diagnosis in these malignant conditions.
  • Examination of the bone marrow leads to the diagnosis: cells are pycnotic, scarcely recognizable in a background of amorphous extracellular eosinophilic proteinaceous material, and histology shows disappearance of fat spaces with preservation of the bone tissue.
  • Tissue hypoxemia due to microcirculation failure may be the main mechanism leading to the necrosis, whatever the related disorder.
  • Supportive care together with specific therapy of the causal disease must be started promptly.
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Monocytic, Acute / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Humans. Male. Necrosis. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039608.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Nakahara C, Nakamura K, Yamanaka N, Baba E, Wada M, Matsunaga H, Noshiro H, Tanaka M, Morisaki T, Katano M: Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in human gastric carcinoma cells. Clin Cancer Res; 2003 Nov 1;9(14):5409-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in human gastric carcinoma cells.
  • PURPOSE: We sought to determine whether cyclosporin-A (CsA) enhances docetaxel [Taxotere (TXT)]- induced apoptosis in human gastric carcinoma cells, and, if so, to determine the relation between this apoptosis and nuclear factor-kappaB (NF-kappaB) activation.
  • EXPERIMENTAL DESIGN: Two human gastric carcinoma cell lines (GCTM-1 and MK-1), a human embryonic pulmonary fibroblast cell line, and human umbilical vein endothelial cells were used as drug targets.
  • The therapeutic effects of a combination of TXT and CsA were assessed in a mouse peritoneal dissemination model.
  • RESULTS: A combination of CsA (5 micro M) and TXT (10 nM) significantly enhanced apoptotic cell death in both carcinoma cell lines but not in nonmalignant cell lines in comparison with the single-agent treatment alone.
  • This effect was not related to drug uptake, efflux, or MDR1 expression.
  • These effects were also observed in freshly obtained TXT-resistant gastric carcinoma cells isolated from a patient with malignant ascites.
  • TXT alone induced NF-kappaB activation in both carcinoma cell types, and this activation was suppressed by CsA.
  • CONCLUSIONS: Treatment with CsA and TXT in combination may be an effective therapeutic strategy for patients with gastric carcinoma.
  • [MeSH-major] Apoptosis / drug effects. Colonic Neoplasms / drug therapy. Cyclosporine / pharmacology. NF-kappa B / antagonists & inhibitors. Stomach Neoplasms / drug therapy. Taxoids / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Animals. Antineoplastic Agents, Phytogenic / pharmacology. Blotting, Western. Caspase Inhibitors. Caspases / metabolism. Chromatography, High Pressure Liquid. Drug Combinations. Enzyme Inhibitors / pharmacology. Female. Humans. Mice. Mice, Inbred BALB C. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614027.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Caspase Inhibitors; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Taxoids; 15H5577CQD / docetaxel; 83HN0GTJ6D / Cyclosporine; EC 3.4.22.- / Caspases
  •  go-up   go-down


9. Takiguchi N, Ishii R, Koda K, Oda K, Miyazaki M: Thymidine phosphorylase expression correlates with malignant potential and anti-tumor effect of doxifluridine on gastric cancer: multivariate analysis for adjuvant chemotherapy doxifluridine vs. 5-fluorouracil. Oncol Rep; 2003 Sep-Oct;10(5):1105-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidine phosphorylase expression correlates with malignant potential and anti-tumor effect of doxifluridine on gastric cancer: multivariate analysis for adjuvant chemotherapy doxifluridine vs. 5-fluorouracil.
  • Doxifluridine (5'-DFUR) is an anticancer drug converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP).
  • We evaluated the relation between TP expression and chemotherapeutic efficacy and prognosis for gastric cancer.
  • Advanced gastric cancer patients given oral adjuvant chemotherapeutics either 5'-DFUR; 163 patients or 5-FU; 162 patients were examined.
  • Multivariate analysis for influencing survival was done, employing variables such as gender, age, procedure, tumor size, location, Borrmann type, histologic factors [type, depth of invasion, lymph node metastasis (n), lymphatic invasion (ly), and venous invasion (v)], drug administered, and TP expression.
  • In conclusion, it was suggested that TP positive gastric cancer with serosal invasion increased malignant potential of the tumor and 5'-DFUR efficacy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Floxuridine / therapeutic use. Fluorouracil / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / metabolism. Thymidine Phosphorylase / biosynthesis
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Prognosis. Risk. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12883665.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 039LU44I5M / Floxuridine; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


10. Nakayama N, Koizumi W, Tanabe S, Sasaki T, Saigenji K: A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). Gastric Cancer; 2006;9(3):185-91
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
  • BACKGROUND: Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions.
  • We evaluated the efficacy of a low dose of cisplatin combined with methotrexate and 5-fluorouracil (MFP therapy) in diffuse-type advanced gastric cancer.
  • The median survival time was 211 days.
  • CONCLUSION: MFP therapy is useful for the management of diffuse-type inoperable and recurrent gastric cancer, even in patients with conditions such as pleural effusion, ascites, or lymphangitis carcinomatosa who have a poor prognosis or cannot eat solid food.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / drug therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Clin Oncol. 1985 Nov;21(11):1321-4 [4076293.001]
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10):1215-7 [3756943.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1263-9 [7999410.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2091-3 [7857709.001]
  • [Cites] Eur J Cancer. 1990 Jan;26(1):63-5 [2138482.001]
  • [Cites] Gan To Kagaku Ryoho. 1992 Jul;19(7):946-53 [1626950.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):327-8 [830420.001]
  • [Cites] Cancer Treat Rep. 1984 Dec;68(12):1497-8 [6542449.001]
  • [Cites] Eur J Surg Oncol. 1987 Jun;13(3):203-6 [3036603.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1277-9 [8067696.001]
  • [Cites] Science. 1979 Sep 14;205(4411):1135-7 [472732.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1695-704 [6161926.001]
  • [Cites] Gastric Cancer. 2000 Aug 4;3(1):19-23 [11984704.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] Ann Oncol. 1991 Nov-Dec;2(10):751-4 [1801881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5663-7 [6160578.001]
  • [Cites] Am J Clin Oncol. 1983 Feb;6(1):35-8 [6682284.001]
  • [Cites] Gan To Kagaku Ryoho. 1987 Aug;14(8):2482-90 [3619460.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):18-22 [6317158.001]
  • [Cites] Cancer Treat Rep. 1985 Apr;69(4):449-50 [4039628.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):52-56 [11957071.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Jun;19(6):717-20 [6683644.001]
  • [Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(3):167-72 [8500219.001]
  • [Cites] Surg Oncol. 1992 Jun;1(3):215-21 [1341254.001]
  • [Cites] Gastric Cancer. 2001;4(4):212-8 [11846065.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):67-8 [2720894.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Cancer Treat Rep. 1982 Sep;66(9):1713-7 [7116348.001]
  • [Cites] Cancer Res. 1973 Dec;33(12):3091-5 [4760525.001]
  • [Cites] Lancet. 1986 Feb 1;1(8475):256-8 [2868265.001]
  • (PMID = 16952036.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Schmid KE, Kornek GV, Schüll B, Raderer M, Lenauer A, Depisch D, Lang F, Scheithauer W: Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie; 2003 Jun;26(3):255-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.
  • BACKGROUND: Treatment with oxaliplatin plus raltitrexed has demonstrated an encouraging therapeutic index in patients with advanced colorectal cancer and malignant pleural mesothelioma.
  • The aim of this multi-institutional study was to determine the antitumor potential of this combination in patients with metastatic gastric cancer failing prior palliative first-line chemotherapy, and to reconfirm its favorable toxicity profile.
  • PATIENTS AND METHODS: 21 patients with metastatic gastric cancer, who progressed while on or within 6 months after discontinuing palliative first-line chemotherapy, participated in this study.
  • Median progression-free and overall survival from the onset of salvage chemotherapy was 2.0 and 4.5 months, respectively.
  • CONCLUSION: Despite reproducibility of a favorable toxicity profile of oxaliplatin + raltitrexed, our data suggest that this combination regimen has no substantial antitumor activity in patients with progressive, chemotherapeutically pretreated metastatic gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Palliative Care. Salvage Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Quinazolines / administration & dosage. Quinazolines / adverse effects. Retreatment. Survival Rate. Thiophenes / administration & dosage. Thiophenes / adverse effects

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger GmbH, Freiburg
  • [CommentIn] Onkologie. 2003 Jun;26(3):214-5 [12845204.001]
  • (PMID = 12845210.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 04ZR38536J / oxaliplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


12. Verreet PR, Schmidt WU, Müller FP: [Primary gastric lymphoma]. Chirurg; 2004 May;75(5):547-56; quiz 557-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric lymphoma].
  • Primary gastric lymphoma derives from a secondary MALT system developing after a reaction of the immune system, e.g. following chronic gastritis induced by Helicobacter pylori.
  • Morphologically, follicular hyperplasia is found in the gastric mucosa.
  • The pathoetiologic model confirms the transformation of a malignant lymphoma from low grade to high grade by demonstrating increasing autonomous proliferation and, finally, uncontrolled dissemination.
  • Modern diagnostic tools are essential for staging and planning an adequate therapeutic strategy.
  • At present, the therapeutic strategies regarding primary lymphoma are under discussion.
  • Nevertheless, the consensus of international medical and surgical associations still recommends surgical therapy with curative intention for low-grade malignant lymphomas staged I 2-II 2.
  • In cases of high-grade malignant lymphoma, conservative therapy is supposed to be similarly successful.
  • The recent success of noninvasive therapeutic concepts seems to justify the application of triple eradication medication in case of Hp infection as well as radio- and chemotherapy in low- and high-grade malignant lymphomas.
  • However, in cases of nonremission or therapy-associated complications such as uncontrollable bleeding or tumor perforation, surgery is the only therapeutic option.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Anti-Ulcer Agents / therapeutic use. Cell Transformation, Neoplastic / pathology. Combined Modality Therapy. Gastrectomy. Gastric Mucosa / pathology. Gastritis / complications. Gastritis / drug therapy. Gastritis / pathology. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Neoplasm Staging. Practice Guidelines as Topic. Prognosis

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):895-901 [10705011.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] Dtsch Med Wochenschr. 1994 Jun 17;119(24):863-8 [8005064.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1255-60 [8608213.001]
  • [Cites] Lancet. 1994 Jun 11;343(8911):1503 [7911202.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):839-46 [8117603.001]
  • [Cites] Praxis (Bern 1994). 1996 Nov 5;85(45):1451-4 [8975356.001]
  • [Cites] Lancet. 1992 Mar 21;339(8795):745-6 [1347613.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Gut. 2003 Jun;52(6):912-3 [12740354.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • (PMID = 15118792.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents
  •  go-up   go-down


13. Urano N, Fujiwara Y, Doki Y, Tsujie M, Yamamoto H, Miyata H, Takiguchi S, Yasuda T, Yano M, Monden M: Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer; 2006;9(1):44-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma.
  • Increased HIF-1alpha expression is associated with malignant potential, and with patient prognosis and response to chemoradiotherapy in some cancer types.
  • METHODS: We investigated the association between HIF-1alpha expression and clinicopathological characteristics, including the expression of VEGF and p53 proteins, in gastric cancer.
  • Furthermore, we analyzed the impact of HIF-1alpha, VEGF, and p53 protein expression on resistance to chemotherapy in advanced gastric cancer.
  • RESULTS: Among 146 specimens from patients with gastric adenocarcinoma, 89 (61.0%), 52 (35.6%), and 102 (69.9%) were positive for HIF-1alpha, p53, and VEGF expression, respectively.
  • Furthermore, overexpression of these proteins was not associated with chemosensitivity in these patients with gastric cancer.
  • CONCLUSION: Our results indicate that overexpression of HIF-1alpha correlates significantly with p53 and VEGF protein expression in patients with gastric cancer; however, this overexpression shows no association with clinicopathological status, patient prognosis, or chemosensitivity.
  • [MeSH-major] Adenocarcinoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Cell Differentiation. Humans. Immunoenzyme Techniques. Lymph Nodes. Lymphatic Metastasis. Neoplasm Invasiveness / pathology. Survival Rate. Tumor Suppressor Protein p53 / metabolism. Up-Regulation. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2004 May;5(5):405-6 [15144945.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 May;14(5):831-8 [3360652.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):215-23 [11804750.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1830-2 [11280732.001]
  • [Cites] Trends Mol Med. 2001 Aug;7(8):345-50 [11516994.001]
  • [Cites] J Biomed Sci. 2005;12(1):229-41 [15864753.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):165-71 [11443623.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5215-22 [11431362.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6548-54 [11522653.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1661-8 [11410504.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1541-5 [10749120.001]
  • [Cites] Pancreas. 2003 Jan;26(1):56-64 [12499918.001]
  • [Cites] Genes Dev. 2000 Feb 15;14 (4):391-6 [10691731.001]
  • [Cites] Nat Med. 2000 Dec;6(12 ):1335-40 [11100117.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Cancer Sci. 2005 Mar;96(3):176-82 [15771621.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):200-8 [15245814.001]
  • [Cites] Biochem J. 2004 Jun 1;380(Pt 2):419-24 [14984367.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 1;128(1):31-4 [11454426.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):946-56 [15199114.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2493-7 [11980639.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2911-6 [11306467.001]
  • [Cites] Circ Res. 1995 Sep;77(3):638-43 [7641334.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3995-4004 [11359907.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3436-44 [11313469.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):34-44 [10640274.001]
  • (PMID = 16557436.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Tumor Suppressor Protein p53; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


14. Li J, Liu P, Wang H, Yu J, Xie P, Liu X: [Clinical analysis of 31 patients with gastric stromal tumors]. Zhonghua Nei Ke Za Zhi; 2002 Nov;41(11):742-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 31 patients with gastric stromal tumors].
  • OBJECTIVE: To investigate the clinical manifestations, diagnosis and treatment of gastric stromal tumors.
  • METHODS: 31 patients with gastric stromal tumors treated from 1993, 1 - 2001, 9 were analyzed retrospectively.
  • The distribution of gastric tromal tumors is fundus > body > antrum.
  • Diagnosis of this condition is sometimes difficult and treatment is often delayed because patients usually present with nonspecific abdominal symptoms.
  • The main manifestations of gastric stromal tumors are upper gastrointestinal hemorrhage 61.3% (19/31), 7 patients with acute hemorrhage and 12 with chronic hemorrhage.
  • Most of them were malignant.
  • Gastroscopy, ultrasound gastroscopy, computed tomography, B type ultrasound and upper gastrointestinal X-ray series are helpful to diagnosis.
  • Gastric stromal tumors exhibit consistent immunohistochemical expressions of CD(117) and/or CD(34).
  • The operative treatment is thought of the first choice.
  • Effect of the chemotherapy isn't satisfied.
  • There is no standard chemotherapy for gastric stromal tumors.
  • CONCLUSIONS: Gastric stromal tumor is a kind of separated submucosal tumor which is different from leiomyoma, leiomyosarcoma and neurogenic tumors.
  • Early diagnosis and rational treatment are the keys to improve the prognosis.
  • [MeSH-major] Stomach Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485519.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR: Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol; 2000;46(2):167-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
  • PATIENTS AND METHODS: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ovarian, head and neck cancer and non-Hodgkin's lymphoma, and as first-line chemotherapy in patients with colorectal and gastric cancer and melanoma.
  • The drug was given as a bolus infusion at a 4-weekly dose of 150 microg/m2.
  • CONCLUSIONS: At this dose and schedule carzelesin did not yield activity in the types of tumors studied.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzofurans / therapeutic use. Indoles / therapeutic use. Neoplasms / drug therapy. Prodrugs / therapeutic use
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Colorectal Neoplasms / drug therapy. Female. Head and Neck Neoplasms / drug therapy. Humans. Infusions, Intravenous. Lymphoma, Non-Hodgkin / drug therapy. Male. Melanoma / drug therapy. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / drug therapy. Stomach Neoplasms / drug therapy


16. Ikeguchi M, Kaibara N: Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. Int J Mol Med; 2001 Dec;8(6):661-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer.
  • The expression of survivin has not been reported in differentiated normal tissues, but it has been observed in many cancerous tissues.
  • Recent studies have revealed that survivin may correlate with the chemo-radio resistance of certain malignant cells.
  • In the present study, the correlation between the occurrence of apoptosis and the level of expression of survivin messenger RNA (mRNA) was investigated in a gastric cancer cell line (MKN-45) and in patients with advanced gastric cancer during cisplatin (CDDP) treatment.
  • In the gastric cancer cell line, the percentage of apoptotic cells (apoptotic index: AI) did not change after 48 h incubation with low-dose CDDP (1 microg/ml), whereas the AI explosively increased between 12 and 24 h treatment with high-dose CDDP (10 microg/ml).
  • Relative levels of expression of survivin mRNA and survivin protein increased after low- and high-dose CDDP treatment.
  • Survivin mRNA was not detected in normal gastric mucosas.
  • Also, in 13 patients with advanced gastric cancer who underwent CDDP-based preoperative chemotherapy, survivin mRNA was detected in only 2 cases (15.4%).
  • However, the clinical importance of survivin expression remains unclear in patients with gastric cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Chromosomal Proteins, Non-Histone / genetics. Cisplatin / pharmacology. Microtubule-Associated Proteins. RNA, Messenger / metabolism. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Dose-Response Relationship, Drug. Female. Gastric Mucosa / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Neoplasm Proteins. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11712083.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Chromosomal Proteins, Non-Histone; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Lordick F, Grenacher L, Röcken C, Ebert M, Moehler M, Schumacher G: [Diagnosis and treatment of gastric cancer]. Dtsch Med Wochenschr; 2010 Aug;135(34-35):1671-82; quiz 1683-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of gastric cancer].
  • [Transliterated title] Diagnostik und Therapie des Magenkarzinoms.
  • From a global perspective, gastric cancer including cancer of the esophago-gastric junction is the fourth most common malignant tumor and the second-most common cause of cancer-related death.
  • Due to the lack of screening programs in Western countries, most gastric cancers are diagnosed in advanced stages.
  • A sophisticated staging should include high-resolution computed tomography of the thorax, abdomen and pelvis and video-documented endoscopy and endoscopic ultrasound.
  • In mucosal gastric cancer, endoscopic resection can replace surgical resection if specific criteria are present.
  • In the stages II and III perioperative chemotherapy has been established as a standard of care and should be applied.
  • In the metastatic setting, treatment goals are palliative.
  • Chemotherapy can prolong survival, improve symptoms and can help to maintain a better quality of life.
  • Combination chemotherapy including a platinum compound and a fluoropyrimidine regarded as standard.
  • About 20 % of gastric cancers exhibit overexpression of the growth factor receptor family member Her2.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / administration & dosage. Endoscopy, Digestive System. Epirubicin / administration & dosage. Esophagectomy. Fluorouracil / administration & dosage. Gastrectomy. Gastric Mucosa / pathology. Humans. Laparoscopy. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 20721843.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FPEPIR regimen
  • [Number-of-references] 40
  •  go-up   go-down


18. Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G: Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc; 2010 May;42(4):1314-6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Malignancies are a well-known complication of immunosuppressive therapy among renal transplant recipients, representing an important cause of long-term morbidity and mortality.
  • Rapamycin has been shown to limit the proliferation of a number of malignant cell lines in vivo and in vitro.
  • METHODS: Fifteen patients developed the following malignancies at a mean of 90.3 months (range = 10-252) after kidney transplantation: metastatic gastric cancer (n = 1), metastatic colon cancer (n = 1), bilateral nephrourothelioma (n = 1), skin cancer (n = 2), Kaposi's sarcoma (n = 2), posttransplant lymphoproliferative disorder (PTLD; n = 4), renal cell carcinoma T1 (n = 1), MALT lymphoma (n = 1), intramucous colon carcinoma (n = 1), liposarcoma of the spermatic cord (n = 1).
  • RESULTS: Both patients with metastatic cancer underwent chemotherapy but succumbed after 6 and 13 months.
  • Two patients with PTLD who underwent chemotherapy died after 12 and 36 months.
  • Nevertheless, it is difficult to assess whether tumor regression was due to rapamycin treatment or to the reduced immunosuppression.
  • [MeSH-major] Kidney Transplantation / immunology. Neoplasms / immunology. Sirolimus / therapeutic use
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms / immunology. Colonic Neoplasms / pathology. Genital Neoplasms, Male / immunology. Genital Neoplasms, Male / pathology. Humans. Immunosuppression / methods. Immunosuppressive Agents / therapeutic use. Liposarcoma / immunology. Liposarcoma / pathology. Male. Neoplasm Metastasis. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Stomach Neoplasms / immunology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Inc.
  • (PMID = 20534289.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


19. Curtis JL, Burns RC, Wang L, Mahour GH, Ford HR: Primary gastric tumors of infancy and childhood: 54-year experience at a single institution. J Pediatr Surg; 2008 Aug;43(8):1487-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric tumors of infancy and childhood: 54-year experience at a single institution.
  • BACKGROUND/PURPOSE: Primary gastric tumors are rare in infancy and childhood.
  • METHODS: During the period extending from 1952 to 2006, 21 infants and children with primary gastric tumors were treated at Children's Hospital Los Angeles.
  • RESULTS: There were 12 males and 9 females, aged 12 days to 18 years, who were diagnosed with gastric tumors.
  • Morphological analysis revealed gastric stromal tumors (n = 6), teratomas (n = 4), lymphomas (n = 4), adenocarcinomas (n = 2), inflammatory myofibroblastic tumors (n = 2), embryonal rhabdomyosarcoma (n = 1), and hamartomas (n = 3).
  • There were 16 patients still alive (mean follow-up, 22.3 months), whereas 6 died from active disease despite multimodal treatment.
  • CONCLUSIONS: Gastric tumors in children are rare.
  • Most malignant tumors present at an advanced stage and carry a substantial rate of mortality.
  • In the case of some malignancies, chemotherapy may play a major role.
  • Metastatic evaluation should be performed in all patients with malignant gastric tumors.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy
  • [MeSH-minor] Adolescent. Anastomosis, Roux-en-Y. Biopsy, Needle. Chemotherapy, Adjuvant. Child. Child, Preschool. Cohort Studies. Combined Modality Therapy. Female. Gastrectomy / methods. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18675640.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Saikawa Y, Kubota T, Maeda S, Otani Y, Kumai K, Kitajima M: Inhibition of DNA methyltransferase by antisense oligodeoxynucleotide modifies cell characteristics in gastric cancer cell lines. Oncol Rep; 2004 Sep;12(3):527-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of DNA methyltransferase by antisense oligodeoxynucleotide modifies cell characteristics in gastric cancer cell lines.
  • In the present study, we designed an antisense oligodeoxynucleotide of DNMT1 (AS/MT: 5'-CGGTAC GCGCCGGCATCT-3') and demonstrated successful inhibition of DNMT1 expression by AS/MT at the protein level, using gastric cancer cell lines in vitro.
  • E-cadherin protein expression was increased, and both cyclin D1 and PCNA were decreased by AS/MT treatment.
  • An in vivo model of peritoneal dissemination using the nude mouse system showed an increased malignant potential of AS/MT treated TMK-1 cells as demonstrated by a greater number of peritoneal tumor nodules in the AS/MT as compared to the NS/MT treated group, 34.8+/-4.3 vs. 22.4+/-3.0 nodules, respectively (p=0.0039).
  • In conclusion, the inhibition of DNA methylation by DNMT1 by an antisense oligodeoxynucleotide influences cell morphology and adhesion, as well as cell growth in gastric cancer cells in vitro.
  • Moreover, these alterations in the characteristics of cancer cells resulted in an increased ability to attach onto the peritoneum in the nude mouse system in vivo, suggesting that strict clinical guidelines will be necessary to utilize such a DNA methylation inhibitor, since it does not always mean a therapeutic antitumor strategy.
  • [MeSH-major] DNA (Cytosine-5-)-Methyltransferase / antagonists & inhibitors. Oligonucleotides, Antisense / pharmacology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Animals. Base Sequence. Blotting, Western. Bromodeoxyuridine / pharmacology. Cadherins / metabolism. Cell Adhesion. Cell Division. Cell Line, Tumor. Cyclin D1 / metabolism. DNA Methylation. Dose-Response Relationship, Drug. Fibroblasts / metabolism. Humans. Immunohistochemistry. Mice. Mice, Nude. Molecular Sequence Data. Neoplasm Invasiveness. Proliferating Cell Nuclear Antigen / metabolism. Signal Transduction. Time Factors


21. Siewert E, Tietze L, Maintz C, Geier A, Dietrich CG, Matern S, Gartung C: [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding]. Z Gastroenterol; 2004 Mar;42(3):233-42
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first case describes an 82-year-old patient with a hemorrhagic shock due to upper gastrointestinal bleeding from a GIST of the stomach.
  • The cases are used to discuss the consequences for therapy and prognosis resulting from the heterogeneity of this tumor entity; the relevant immunohistochemical markers used to distinguish between various tumor subtypes of gastrointestinal mesenchymal tumors (GIMT) are listed.
  • The third case of a 40-year-old patient with a malignant GIST recurrence after surgery and exhibiting secondary resistance after one year of successful therapy with the receptor tyrosine kinase inhibitor imatinib (Gleevec), antagonizing pathogenetically relevant constitutive c-KIT activation, illustrates the potential and limitations of the only effective drug treatment for advanced GIST.
  • [MeSH-major] Abdominal Pain / etiology. Cardia. Esophageal Neoplasms / diagnosis. Gastrointestinal Hemorrhage / etiology. Neoplasms, Connective Tissue / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Benzamides. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Esophagectomy. Female. Gastrectomy. Gastric Mucosa / pathology. Gastroscopy. Humans. Imatinib Mesylate. Incidental Findings. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Piperazines / therapeutic use. Polyps / diagnosis. Polyps / drug therapy. Polyps / pathology. Polyps / surgery. Prognosis. Proto-Oncogene Proteins c-kit / analysis. Pyrimidines / therapeutic use. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Shock, Hemorrhagic / etiology. Stromal Cells / pathology. Tomography, X-Ray Computed. Treatment Outcome


22. Arai W, Hosoya Y, Hyodo M, Haruta H, Kurashina K, Saito S, Hirashima Y, Yokoyama T, Zuiki T, Sakuma K, Yasuda Y, Nagai H: Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1. Int J Clin Oncol; 2007 Apr;12(2):146-9
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1.
  • BACKGROUND: Many patients with gastric cancer respond to TS-1, but some fail to respond or have recurrence.
  • Second-line therapy is needed.
  • METHODS: We performed a pilot study in patients with advanced gastric cancer who did not respond to TS-1 or who had disease recurrence.
  • The treatment was repeated until disease progression or prohibitive toxicity.
  • Response rate, duration of response, median survival time (MST), effects on pleural effusion, ascites, and other signs, and toxicity were evaluated.
  • The MST after the start of second-line treatment was 175 days (95% confidence interval, 135 to 224 days).
  • Hair loss occurred in 32 patients (62%), and leukopenia developed in 28 (54%, grade 3 in 1 patient and grade 2 or lower in the others).
  • The MST after the start of treatment with TS-1 was about 16 months.
  • CONCLUSION: A combination of doxifluridine and weekly paclitaxel is expected to be an effective second-line treatment for gastric cancer not responding to TS-1, especially in patients with malignant ascites or pleural effusion.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Silicates / therapeutic use. Stomach Neoplasms / drug therapy. Titanium / therapeutic use
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / secondary. Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Floxuridine / administration & dosage. Floxuridine / adverse effects. Humans. Japan. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Pilot Projects. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):32-4 [9007118.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Gastric Cancer. 2002;5(2):90-5 [12111584.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):322-5 [15783060.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Dec;29(13):2555-9 [12506482.001]
  • [Cites] Gastric Cancer. 2006;9(1):14-8 [16557431.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):138-44 [15827767.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1291-6 [15865080.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3353-61 [9779712.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):416-9 [9708646.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Nov;29(11):2005-8 [12465405.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):685-90 [9485021.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 14):10-3 [11605177.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Jan;30(1):133-9 [12557719.001]
  • [Cites] Gan. 1980 Feb;71(1):112-23 [6445847.001]
  • [Cites] Ann Oncol. 1994 Feb;5(2):189-90 [8186165.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-62-S15-67 [9346225.001]
  • [Cites] J Med Chem. 1979 Nov;22(11):1330-5 [533880.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1133-7 [11583196.001]
  • (PMID = 17443283.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Silicates; 039LU44I5M / Floxuridine; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


23. Ninomiya S, Inomata M, Tajima M, Ali AT, Ueda Y, Shiraishi N, Kitano S: Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice. J Surg Res; 2009 Jun 15;154(2):196-202
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice.
  • BACKGROUND: The aim of this study was to clarify the effect of bevacizumab on gastric cancer with peritoneal metastasis in nude mice.
  • MATERIALS AND METHODS: The expression of vascular endothelial growth factor mRNA (VEGF mRNA) in four gastric cancer cell lines, NCI-N87, MKN-45, MKN-45P, and Kato-III, was examined by polymerase chain reaction.
  • We created a model of peritoneal metastasis by injecting mice with the human gastric cancer cell line MKN-45P.
  • Mice were injected intraperitoneally with bevacizumab (0.1 mg/100 microL) on days 5-14, after inoculation (n = 10) or with phosphate-buffered saline (PBS) over the same time period (n = 10).
  • CONCLUSIONS: These results show that intraperitoneal administration of bevacizumab inhibits peritoneal metastasis and reduces malignant ascites in tumor-bearing mice.
  • [MeSH-major] Adenocarcinoma / secondary. Angiogenesis Inhibitors / pharmacology. Antibodies, Monoclonal / pharmacology. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology. Vascular Endothelial Growth Factor A / immunology
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Bevacizumab. Cell Line, Tumor. Disease Models, Animal. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329124.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


24. Maruyama M, Toukairin Y, Baba H, Kure N, Nagahama T, Ebuchi M: [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers]. Gan To Kagaku Ryoho; 2001 Oct;28(11):1505-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].
  • We studied the pharmacokinetics of the intraperitoneal administration of CPT-11 for four patients with peritoneal metastasis (2 gastric cancer cases, 2 colon cancer cases).
  • Intraperitoneal therapy with CPT-11 was effective for the control of malignant ascites.
  • The high concentration of CPT-11 was achieved with intraperitoneal therapy and a small fraction of CPT-11 changed into SN-38 in the abdominal cavity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacokinetics. Camptothecin / analogs & derivatives. Camptothecin / pharmacokinetics. Colonic Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Injections, Intraperitoneal. Male. Middle Aged. Neoplasm Seeding

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707965.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Kunisaki Y, Muta T, Yamano Y, Kobayashi Y: Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion. Int J Hematol; 2003 Nov;78(4):357-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of two cell populations corresponding to distinct maturation stages in API-2/MLT-positive mucosa-associated lymphoid tissue lymphoma cells proliferating in pleural effusion.
  • Computed tomography scans showed extensive thickening of the gastric wall and bilateral massive PE without lymph node or pulmonary involvement.
  • A histologic examination of the gastric mucosa showed a diffuse infiltration of small- to medium-sized lymphoid CD20-bearing cells, some of which showed a plasmacytoid morphology.
  • The diagnosis was gastric mucosa-associated lymphoid tissue (MALT) lymphoma infiltrating to the PE, PB, and BM.
  • The patient had a good response to fludarabine treatment, which was followed with rituximab therapy.
  • In general, gastric MALT lymphoma cells have a tendency to differentiate into plasma cells.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Oncogene Proteins, Fusion / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Aged. Antigens, Differentiation, B-Lymphocyte / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. B-Lymphocytes / pathology. Cell Adhesion Molecules / analysis. Cell Differentiation. Cell Division. Humans. Immunophenotyping. Male. Neoplasm, Residual. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3944-8 [9307277.001]
  • [Cites] Blood. 2002 Jan 1;99(1):3-9 [11756145.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2019-27 [10595932.001]
  • [Cites] Mod Pathol. 2001 Aug;14(8):798-805 [11504840.001]
  • [Cites] Int J Hematol. 2002 Dec;76(5):385-93 [12512832.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] Rinsho Ketsueki. 2000 Nov;41(11):1183-8 [11193437.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):588-94 [11736940.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40 [11842387.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):683-90 [11710684.001]
  • [Cites] Gut. 2001 Oct;49(4):519-25 [11559649.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1583-93 [9137085.001]
  • [Cites] Br J Haematol. 1997 Jun;97(3):515-22 [9207392.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):301-9 [10760689.001]
  • [Cites] Leuk Res. 1990;14(7):617-22 [2388473.001]
  • [Cites] Acta Otolaryngol Suppl. 1996;523:259-62 [9082801.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Mar;117(2):113-7 [10704680.001]
  • [Cites] Cell. 1993 Jul 16;74(1):185-95 [7687523.001]
  • (PMID = 14686495.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Cell Adhesion Molecules; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


26. Cappell MS: Risk factors and risk reduction of malignant seeding of the percutaneous endoscopic gastrostomy track from pharyngoesophageal malignancy: a review of all 44 known reported cases. Am J Gastroenterol; 2007 Jun;102(6):1307-11
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors and risk reduction of malignant seeding of the percutaneous endoscopic gastrostomy track from pharyngoesophageal malignancy: a review of all 44 known reported cases.
  • Pathologically proven stomal metastases were located in the abdominal wall (PEG exit site) in 63%, in the gastric wall (PEG entrance site) in 7%, and in both walls in 30%.
  • Therapeutic risk factors for stomal metastases included: (a) endoscopic PEG placement (in 98%, surgical gastrostomy in 2%);.
  • (c) primary cancer untreated or known local recurrence after treatment before PEG (in 87%); and (d) time>or=3 months after PEG insertion (in 100%, <3 months in 0%; mean interval 7.8+/-5.2 months after PEG).
  • Four of the currently reported risk factors are novel (pathologic factors d,e; therapeutic factors a,d).
  • The risk may be reduced in patients with risk factors by radiotherapy, chemotherapy, or cancer surgery before PEG; by substituting the push-guidewire for the pull-string technique for PEG; and possibly by use of a sheath with the pull-string technique.
  • [MeSH-major] Endoscopy, Gastrointestinal / adverse effects. Esophageal Neoplasms / pathology. Gastrostomy / adverse effects. Neoplasm Seeding. Pharyngeal Neoplasms / pathology
  • [MeSH-minor] Abdominal Wall / pathology. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Risk Factors. Risk Reduction Behavior. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488255.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Yang Y, Lee JH, Kim KY, Song HK, Kim JK, Yoon SR, Cho D, Song KS, Lee YH, Choi I: The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. Cancer Lett; 2005 Apr 28;221(2):191-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells.
  • As an effort to identify immune suppressive molecules in gastric cancer cells, a signal sequence trap was employed.
  • Among the genes identified, 9-27 gene was highly expressed in gastric tumor tissues and in cancer cell lines.
  • It was induced by IFN-gamma treatment, but not by TNF-alpha or TGF-beta1 treatment.
  • The overexpression of 9-27 in the gastric cancer cells rendered tumor cells more resistant to natural killer cells.
  • Taken together, these data indicate that 9-27 plays a role in malignant progression by suppressing natural killer cells and by increasing the invasive potential of gastric cancer cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Movement / drug effects. Interferon-gamma / pharmacology. Killer Cells, Natural / drug effects. Membrane Proteins / metabolism. Neoplasm Invasiveness / pathology. Stomach Neoplasms / immunology
  • [MeSH-minor] Adenocarcinoma / immunology. Adenocarcinoma / therapy. Antigens, Differentiation. Gene Expression Profiling. Humans. Transforming Growth Factor beta / pharmacology. Transforming Growth Factor beta1. Tumor Cells, Cultured / drug effects. Tumor Necrosis Factor-alpha / pharmacology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808405.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Antineoplastic Agents; 0 / Membrane Proteins; 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / Tumor Necrosis Factor-alpha; 0 / leu-13 antigen; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


28. Siersema PD, Schrauwen SL, van Blankenstein M, Steyerberg EW, van der Gaast A, Tilanus HW, Dees J, Rotterdam Esophageal Tumor Study Group: Self-expanding metal stents for complicated and recurrent esophagogastric cancer. Gastrointest Endosc; 2001 Nov;54(5):579-86
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fewer complications are encountered with the use of self-expanding metal stents compared with semirigid prostheses in the palliation of patients with malignant esophagogastric obstructions.
  • METHODS: Covered metal stents were placed in 57 patients for the following reasons: esophagorespiratory fistula (n = 16), recurrent carcinoma in a gastric tube interposition (n = 21), recurrent carcinoma after partial (n = 4) or total (n = 6) gastrectomy, or a carcinoma near the upper esophageal sphincter (n = 10).
  • RESULTS: The procedure was technically successful in 55 of 57 (96%) patients.
  • Tumor recurred in 5 of 16 patients with a fistula, 8 of 21 patients after gastric tube interposition, 3 of 10 patients after gastrectomy, and 2 of 10 patients with a tumor immediately distal to the upper esophageal sphincter.
  • Prior radiation, chemotherapy, or both increased the risk of specific stent-related complications in relation to the (neo)esophagus (6 of 16 [38%] versus 4 of 41 [10%]: odds ratio, 5.5: 95% CI [1.3, 24], p = 0.018).
  • [MeSH-major] Esophageal Neoplasms / surgery. Palliative Care. Stents. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Deglutition Disorders / etiology. Deglutition Disorders / prevention & control. Esophageal Fistula / etiology. Esophageal Fistula / surgery. Esophagectomy. Female. Gastrectomy. Humans. Logistic Models. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Postoperative Complications. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11677473.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Izutani R, Kato M, Asano S, Imano M, Ohyanagi H: Expression of manganese superoxide disumutase influences chemosensitivity in esophageal and gastric cancers. Cancer Detect Prev; 2002;26(3):213-21
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of manganese superoxide disumutase influences chemosensitivity in esophageal and gastric cancers.
  • In vivo studies demonstrated that the combined administration of TGFbeta1 and ADM delayed tumor growth better than either treatment alone.
  • Thus, combined administration of TGFbeta1 and ADM might prove useful for treatment of malignant disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / enzymology. Neoplasm Proteins / metabolism. Stomach Neoplasms / drug therapy. Stomach Neoplasms / enzymology. Superoxide Dismutase / metabolism
  • [MeSH-minor] Animals. Computer Graphics. Disease Models, Animal. Female. Humans. Mice. Mice, Nude. Statistics, Nonparametric. Transforming Growth Factor beta / therapeutic use. Transforming Growth Factor beta1. Tumor Cells, Cultured / drug effects. Tumor Necrosis Factor-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12269769.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / TGFB1 protein, human; 0 / Tgfb1 protein, mouse; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down






Advertisement